Jarushka Naidoo: Clinical + genetic factors associated with Type I diabetes from ICIs

Jarushka Naidoo shared a post on X:

“Clinical + genetic factors associated with Type I diabetes from ICIs in JAMA Oncology.

• Of 14328pts, incidence 0.45%
• 3 phenotypes of T1DM exist, based on Ab & C-peptide(B): Ab+B-=earlier onset, increase DKA
• T1DGRS2 polygenic risk score = 4.4 fold increase risk.”

Identification of Immune Checkpoint Inhibitor–Induced Diabetes

Authors: Karina N. Ruiz-Esteves, MD, Kaitlyn R. Shank, MD, Aaron J. Deutsch, MD, Alekhya Gunturi, BA, Natalia Chamorro-Pareja, MD, Caitlin A. Colling, MD, Leyre Zubiri, MD, PhD, Katherine Perlman, MPH, Tianqi Ouyang, MPH, Alexandra-Chloé Villani, PhD, Jose C. Florez, MD, PhD, Alexander Gusev, PhD, Kerry L. Reynolds, MD, Karen K. Miller, MD, Miriam S. Udler, MD, PhD, Meghan E. Sise, MD, MS, Michelle Rengarajan, MD, PhD.

Source: Jarushka Naidoo/X

Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials.

She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.